Grünenthal

Company snapshot

Grünenthal GmbH is a German [pharmaceutical company](en.wikipedia.org/wiki/Pharmaceutical_com) headquartered in [Aachen](en.wikipedia.org/wiki/Aachen) in Germany. It was founded in 1946 as Chemie Grünenthal and has been continuously [family-owned](en.wikipedia.org/wiki/Family_business). The company was the first to introduce [penicillin](en.wikipedia.org/wiki/Penicillin) into the German market in

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Grünenthal. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Grünenthal.

1. Jun 8, 2026 Clinical update

   HP6019-07 — Phase 1

2. Jun 8, 2026 Clinical update

   HP7040-01 — Phase 1

3. May 26, 2026 Clinical update

   RTX-GRT7039, Naropin® 5 mg/ml Injektionslösung — Phase 3

View all clinical trial activity →

• What is Grünenthal?

  Gruenenthal is a pharma organization headquartered in EU. Primary therapeutic focus areas include Moderate to severe pain associated with Osteoarthritis of the knee, Not applicable for phase I study. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent reco

• Is Grünenthal publicly traded?

  Grünenthal appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Grünenthal develop or market?

  We link 5 drug profile(s) where Grünenthal is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/gruenenthal-gmbh#company-drugs.

• What are the latest developments for Grünenthal?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Grünenthal focus on?

  Grünenthal focuses on Moderate to severe pain associated with Osteoarthritis of the knee, Not applicable for phase I study based on our analysis of their pipeline programs and drug development activities.